Mycofenolaat Mofetil Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycofenolaat Mofetil Accord, is an antimetabolite immunosuppressant presented as an oral tablet for oral use. It is employed to prevent organ transplant rejection and to treat lupus nephritis in adult patients.

GNH USA supplies Mycofenolaat Mofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, with distribution across EU and other regulated markets. The company ensures quality compliance with EU pharmacopeial standards.

Mycophenolate Mofetil is used in immunosuppressive therapy for conditions involving the immune system.

- Organ transplant rejection: reduces the risk of acute rejection and supports graft survival. - Lupus nephritis: improves renal function and slows disease progression. - Solid organ transplantation: helps maintain long‑term graft function across kidney, liver and heart transplants.

Mycophenolate Mofetil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools often occurring early in therapy. - Headache: transient cranial discomfort. - Tremor: fine shaking of the hands. - Abdominal pain: cramp‑like discomfort. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Opportunistic infections: increased susceptibility to viral, fungal or bacterial pathogens. - Bone‑marrow suppression: leukopenia, anemia or thrombocytopenia. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Malignancy: heightened risk of post‑transplant lymphoproliferative disorder. - Severe allergic reactions: rash, angioedema or anaphylaxis.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor blood counts: perform regular complete blood count assessments. - Assess renal function: evaluate serum creatinine and glomerular filtration rate. - Pregnancy risk: avoid use in pregnancy; advise effective contraception. - Hepatic impairment: adjust dose or monitor liver enzymes closely. - Live vaccines: contraindicated due to immunosuppression. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Mycophenolate Mofetil interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Rifampin or other strong CYP3A4 inducers: markedly reduce mycophenolate exposure. - Azathioprine: additive myelosuppression risk. - Live vaccines: increased risk of infection. - Cholestyramine or bile‑acid sequestrants: decrease oral absorption.

Moderate Interactions (Monitor Closely): - Antacids (e.g., aluminum‑magnesium): may lower bioavailability. - ACE inhibitors or ARBs: heightened potential for renal dysfunction. - NSAIDs: increased risk of nephrotoxicity when combined with mycophenolate.